Dorothea Holzwarth
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dorothea Holzwarth has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
Janbernd Kirschner
2 shared publications- Alexander Mensch
Department of Neurology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany
1 shared publication - Andrea Bevot
Clinic for Paediatrics and Adolescent Medicine, Department of Neuropaediatrics, General Paediatrics, Diabetology, Endocrinology, Social Paediatrics, University Hospital Tübingen, Tübingen, Germany
1 shared publication - Andreas Hahn
Department of Child Neurology, Justus-Liebig-University Giessen, Germany
1 shared publication - Andreas Merkenschlager
Department of Women and Child Health, Hospital for Children and Adolescents and Center for Pediatric Research (CPL), Leipzig University, 04103 Leipzig, Germany
1 shared publication - Andreas Panzer
Department of Pediatric Radiology, Vestische Kinder-und Jugendklinik Datteln, University of Witten-Herdecke, Datteln, Germany
1 shared publication
Latest Publications
- Open Access
- 5 February 2026
- Published by Elsevier in SSRN Electronic Journal
Real-World Outcomes of Risdiplam in 5q Spinal Muscular Atrophy Over 30 Months in Adolescents and Adults: A Multicentre, Prospective, Observational SMArtCARE Study
Background: Risdiplam is approved for the treatment of 5q-SMA from birth for all types and stages. However, broader data for adults are scarce. We aimed to assess safety and efficacy of risdiplam in adults with SMA.Methods: This is an observational cohort study at 38 academic clinical sites in German-speaking countries. Patients with genetically confirmed 5q-SMA (age 16–69 years) were included and received risdiplam treatment for a minimum treatment time of 6 months to a follow-up of up to 30 months. Primary outcome was the change in the total Revised Upper Limb Module (RULM) score, assessed at baseline to months 4-6, 12-14 and 28-30, and based on pre–post comparisons. This study is registered with the German Clinical Trials Register (DRKS00012699).Findings: Risdiplam showed significant motor improvement across a wide phenotypic spectrum of adult SMA patients regardless of age, SMN2 copy number, and functional status. 74% of patients improved or stabilized at 30 months in RULM; patients do not only deteriorate less rapidly but continue to stabilize or even improve at later time points. Maximum RULM improvement was 1.37 points in SMA3 patients at month 12/14, while at all other timepoints, both in SMA1 and SMA2 patients, mean RULM improvement was below 1 and at all time points below the CMC of 2. We did not detect a correlation between RULM improvement and age, sex or body weight, nor significant changes in HFMSE and 6MWT. No new safety findings were detected.Interpretation: Our study provides real-world data from the multinational SMArtCARE registry on efficacy and safety of risdiplam in 194 adult ambulatory and non-ambulatory SMA patients over 4-30 months of treatment.Funding: Financial support for the SMArtCARE registry is provided by Biogen, Novartis and Roche. Declaration of Interest: BS, BK, CB, CS, CR, EH, GSa, GS, MS, OS and VP declare no conflicts of interest. AB received honoraria for advisory board attendance, speaker’s fees from Biogen, Novartis, Roche, Italpharmaco, SantheraMT received honoraria for advisory board attendance, speaker’s fees and research funding from Alexion, Amicus, AstraZeneca, Sanofi Genzyme, Takeda, outside of the present work. AE received speakers´ fees and honoraria for advisory board attendance from Novartis, Biogen, Roche AH received funding for Travel and/or Speaker Honoraria from Roche, Biogen, Novartis, PTC Therapeutics, Santhera, Biomarin, and Takeda. He received research support from Roche, Sanofi, Takeda, Biomarin. AR received speaker fees from Amylyx Pharmaceuticals, ROCHE, Argenx, UCB Pharma, Alexion Pharma, Zambon and ITF Pharma, travel support for congress from Zambon and Johnson&Johnson and served on advisory boards for Biogen and Argenx, outside of the submitted work. ASN reports Adborad Meetings with Roche, Biogen, Novartis and Santhera Pharmaceuticals. CN received honoraria for advisory board attendance, speaker’s fees and travel grants from Biogen USA, Biogen Switzerland, Roche, Sanofi Genezyme, Mitsubishi Tanabe, Alexion, Argenx, Amicus, Johnson & Johnson, Amgen, Jannsen DH received honoraria for advisory board attendance from Novartis. DZ received honoraria for advisory board attendance from Biogen and Amicus, for consultancy from Novartis, and travel support for conference attendance from Zambon, outside of the present work. FK received speaker honoraria from Roche, Amicus, Alexion, Sanofi; travel support for conference attendance from Roche, ITF Pharma and Amicus, and served on advisory boards for Amicus, Roche, and Abcuro. GMzH received compensation for serving on scientific advisory boards (JnJ, Immunovant), speaker honoraria (Amgen, Argenx) and scientific project funding (Biogen). GW has received honoraria for advisory board attendance, speaker’s fees from Roche, Novartis, Alnylam and AstraZeneca outside of the present work. HC received honoraria for advisory board attendance, speaker’s fees and research funding from Biogen, Novartis, and Roche. HK is serving on a scientific advisory board for Novartis and Scholar Rock and received travel expenses and speaker honoraria from Biogen, Pfizer, Roche, and Sanofi-Aventis. HLo received support for research projects and clinical trials from Amplo Biotechnology, AMO Pharma, argenx, Biogen, Desitin, Fulcrum Therapeutics, Harmony Biosciences, KYE Pharmaceuticals, Milo Biotechnology, Novartis, Pfizer, PTC Therapeutics, Hoffman-La Roche Limited, Sanofi-Genzyme, Santhera, Sarepta, Satellos, Spark Therapeutics and Ultragenyx. HL is the Editor-in-chief for the Journal of Neuromuscular Diseases (IOS Press). JJ received compensation for advisory boards and funding for travel or speaker honoraria from Avexis/Novartis, Biogen, IFT, Roche, PTC, Pfizer, Santhera and Sarepta Therapeutics. JKi received honoraria for advisory board attendance, speaker’s fees and research funding from Biogen, Novartis, ScholarRock and Roche. JK received support to attend scientific conferences or meetings from Roche KV received honoraria for lectures, travel expenses, and/or served as a consultant on advisory boards for Novartis, Roche, Biogen, Santhera, Sanofi, ITF, and Scholar Rock. MA received honoraria fro Roche for advisory board attendance. MB received compensation for advisory board attendance and speaker´s honoraria from Novartis, Biogen, Roche and ITF Pharma. MCW has served on advisory boards for Avexis, Biogen, Novartis, Pfizer, PharNext, PTC Therapeutics, Roche, Santhera, Sarepta, Ultragenyx, Wave Sciences, received funding for Travel or Speaker Honoraria from Biogen, Novartis, PTC Therapeutics, Santhera, and worked as an ad-hoc consultant for Affinia, Audentes Therapeutics, Avexis, Biogen, BridgeBio, Edgewise, Fulcrum, Grünenthal, ML Bio, Novartis, Pfizer, PharNEXT, PTC Therapeutics, Roche. MD has received speaker fees, advisory board and consultant honoraria from Biogen, Hoffmann-La Roche, Sanofi and AstraZeneca, outside of the present work....
- 5 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessReal-World Outcomes of Risdiplam in 5q Spinal Muscular Atrophy Over 30 Months in Adolescents and Adults: A Multicentre, Prospective, Observational SMArtCARE Study
Background: Risdiplam is approved for the treatment of 5q-SMA from birth for all types and stages. However, broader data for adults are scarce. We aimed to assess safety and efficacy of risdiplam in adults with SMA.Methods: This is an observational cohort study at 38 academic clinical sites in German-speaking countries. Patients with genetically confirmed 5q-SMA (age 16–69 years) were included and received risdiplam treatment for a minimum treatment time of 6 months to a follow-up of up to 30 months. Primary outcome was the change in the total Revised Upper Limb Module (RULM) score, assessed at baseline to months 4-6, 12-14 and 28-30, and based on pre–post comparisons. This study is registered with the German Clinical Trials Register (DRKS00012699).Findings: Risdiplam showed significant motor improvement across a wide phenotypic spectrum of adult SMA patients regardless of age, SMN2 copy number, and functional status. 74% of patients improved or stabilized at 30 months in RULM; patients do not only deteriorate less rapidly but continue to stabilize or even improve at later time points. Maximum RULM improvement was 1.37 points in SMA3 patients at month 12/14, while at all other timepoints, both in SMA1 and SMA2 patients, mean RULM improvement was below 1 and at all time points below the CMC of 2. We did not detect a correlation between RULM improvement and age, sex or body weight, nor significant changes in HFMSE and 6MWT. No new safety findings were detected.Interpretation: Our study provides real-world data from the multinational SMArtCARE registry on efficacy and safety of risdiplam in 194 adult ambulatory and non-ambulatory SMA patients over 4-30 months of treatment.Funding: Financial support for the SMArtCARE registry is provided by Biogen, Novartis and Roche. Declaration of Interest: BS, BK, CB, CS, CR, EH, GSa, GS, MS, OS and VP declare no conflicts of interest. AB received honoraria for advisory board attendance, speaker’s fees from Biogen, Novartis, Roche, Italpharmaco, SantheraMT received honoraria for advisory board attendance, speaker’s fees and research funding from Alexion, Amicus, AstraZeneca, Sanofi Genzyme, Takeda, outside of the present work. AE received speakers´ fees and honoraria for advisory board attendance from Novartis, Biogen, Roche AH received funding for Travel and/or Speaker Honoraria from Roche, Biogen, Novartis, PTC Therapeutics, Santhera, Biomarin, and Takeda. He received research support from Roche, Sanofi, Takeda, Biomarin. AR received speaker fees from Amylyx Pharmaceuticals, ROCHE, Argenx, UCB Pharma, Alexion Pharma, Zambon and ITF Pharma, travel support for congress from Zambon and Johnson&Johnson and served on advisory boards for Biogen and Argenx, outside of the submitted work. ASN reports Adborad Meetings with Roche, Biogen, Novartis and Santhera Pharmaceuticals. CN received honoraria for advisory board attendance, speaker’s fees and travel grants from Biogen USA, Biogen Switzerland, Roche, Sanofi Genezyme, Mitsubishi Tanabe, Alexion, Argenx, Amicus, Johnson & Johnson, Amgen, Jannsen DH received honoraria for advisory board attendance from Novartis. DZ received honoraria for advisory board attendance from Biogen and Amicus, for consultancy from Novartis, and travel support for conference attendance from Zambon, outside of the present work. FK received speaker honoraria from Roche, Amicus, Alexion, Sanofi; travel support for conference attendance from Roche, ITF Pharma and Amicus, and served on advisory boards for Amicus, Roche, and Abcuro. GMzH received compensation for serving on scientific advisory boards (JnJ, Immunovant), speaker honoraria (Amgen, Argenx) and scientific project funding (Biogen). GW has received honoraria for advisory board attendance, speaker’s fees from Roche, Novartis, Alnylam and AstraZeneca outside of the present work. HC received honoraria for advisory board attendance, speaker’s fees and research funding from Biogen, Novartis, and Roche. HK is serving on a scientific advisory board for Novartis and Scholar Rock and received travel expenses and speaker honoraria from Biogen, Pfizer, Roche, and Sanofi-Aventis. HLo received support for research projects and clinical trials from Amplo Biotechnology, AMO Pharma, argenx, Biogen, Desitin, Fulcrum Therapeutics, Harmony Biosciences, KYE Pharmaceuticals, Milo Biotechnology, Novartis, Pfizer, PTC Therapeutics, Hoffman-La Roche Limited, Sanofi-Genzyme, Santhera, Sarepta, Satellos, Spark Therapeutics and Ultragenyx. HL is the Editor-in-chief for the Journal of Neuromuscular Diseases (IOS Press). JJ received compensation for advisory boards and funding for travel or speaker honoraria from Avexis/Novartis, Biogen, IFT, Roche, PTC, Pfizer, Santhera and Sarepta Therapeutics. JKi received honoraria for advisory board attendance, speaker’s fees and research funding from Biogen, Novartis, ScholarRock and Roche. JK received support to attend scientific conferences or meetings from Roche KV received honoraria for lectures, travel expenses, and/or served as a consultant on advisory boards for Novartis, Roche, Biogen, Santhera, Sanofi, ITF, and Scholar Rock. MA received honoraria fro Roche for advisory board attendance. MB received compensation for advisory board attendance and speaker´s honoraria from Novartis, Biogen, Roche and ITF Pharma. MCW has served on advisory boards for Avexis, Biogen, Novartis, Pfizer, PharNext, PTC Therapeutics, Roche, Santhera, Sarepta, Ultragenyx, Wave Sciences, received funding for Travel or Speaker Honoraria from Biogen, Novartis, PTC Therapeutics, Santhera, and worked as an ad-hoc consultant for Affinia, Audentes Therapeutics, Avexis, Biogen, BridgeBio, Edgewise, Fulcrum, Grünenthal, ML Bio, Novartis, Pfizer, PharNEXT, PTC Therapeutics, Roche. MD has received speaker fees, advisory board and consultant honoraria from Biogen, Hoffmann-La Roche, Sanofi and AstraZeneca, outside of the present work....
- 25 September 2025
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 59, 18-22
Evolution of neuroimaging features in children with acute flaccid myelitis compared to other forms of childhood myelitis
- 25 September 2025
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 59, 18-22
Evolution of neuroimaging features in children with acute flaccid myelitis compared to other forms of childhood myelitis
- Open Access
- 15 February 2025
- Published by Elsevier in Molecular Therapy
- Vol. 33 (6) , 2842-2850
Pilocytic astrocytoma in a child with spinal muscular atrophy treated with onasemnogene abeparvovec
- 15 February 2025
- Published by Elsevier in Molecular Therapy
- Vol. 33 (6) , 2842-2850
Open AccessPilocytic astrocytoma in a child with spinal muscular atrophy treated with onasemnogene abeparvovec
- 27 July 2023
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 116, 74-80
Whole-Exome sequencing identifies GYS2 biallelic variants in individuals with suspected epilepsy
- 27 July 2023
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 116, 74-80
Whole-Exome sequencing identifies GYS2 biallelic variants in individuals with suspected epilepsy